Out-of-Pocket Prescribed Drug Costs Among Elderly Women

描述：支付处方药正在成为一个重要的， 美国老年人面临的日益严重的问题。自付处方药（OOP-PD） 支出给老年妇女带来了不成比例的负担，但很少有研究表明， 提供了关于这一负担的决定因素的详细和最新资料。 本研究估计了妇女医疗保险的OOP-PD支出负担 65岁以上的受益人，使用全国代表性数据。OOP-PD负荷 将与收入挂钩。拟议项目将探讨 老年妇女OOP-PD负担的模式和相关性 医疗保险当前受益人调查（MCBS）的数据。 拟议的项目将估计高血压老年妇女的比例， OOP-PD负担以及卫生保健获得问题如何影响OOP-PD负担 老年妇女的分组。目标包括：OOP-PD的发展趋势是什么 从1992年起，全国有代表性的老年妇女样本的负担 到1998年？OOP-PD高负荷的预测因素是否发生变化， 从1992年到1998年的时间？在老年妇女中， 女性特有的慢性疾病，如骨质疏松症， 高OOP-PD负荷？MCBS中的OOP-PD支出与数据相比如何 来自其他国家代表性数据集，如医疗支出 小组调查（MEPS）？检查OOP-PD负担的决定因素， 方式可以帮助决策者了解需求的来源， 进一步协助评估处方药的替代解决方案 问题.

DESCRIPTION: Paying for prescription drugs is becoming a significant and growing problem for older Americans. Out-of-pocket prescription drugs (OOP-PD) spending places a disproportionate burden on older women, yet few studies have provided detailed and current information on the determinants of that burden. The present study estimates OOP-PD expenditures burden by women Medicare beneficiaries over age 65, using nationally representative data. OOP-PD burden will be measured in relation to income. The proposed project will explore patterns and correlates of OOP-PD burden among older women using longitudinal data from the multiple years of Medicare Current Beneficiary Survey (MCBS). The proposed project will estimate the proportion of elderly women with high OOP-PD burden and how health care access problems affect OOP-PD burden among subgroups of elderly women. The aims include: what were the trends in OOP-PD burden in a nationally representative sample of elderly women from 1992 through 1998? Was there a change in the predictors of high OOP-PD burden over time from 1992 through 1998? Among elderly women, who have been diagnosed with chronic conditions specific to women such as osteoporosis what factors predict high OOP-PD burden? And how do OOP-PD expenditures in MCBS compare with data from other nationally representative datasets such as Medical Expenditure Panel Survey (MEPS)? Examining the determinants of OOP-PD burden in this manner can assist policy-makers in understanding the sources of need for further assistance with evaluating alternative solutions to prescription drug issues.